🇺🇸 Intrathecal Methotrexate in United States
11 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 11
Most-reported reactions
- Pulmonary Embolism — 2 reports (18.18%)
- Anal Ulcer — 1 report (9.09%)
- Anorectal Discomfort — 1 report (9.09%)
- Clostridium Test Positive — 1 report (9.09%)
- Diarrhoea — 1 report (9.09%)
- Drug Toxicity — 1 report (9.09%)
- Dyspnoea — 1 report (9.09%)
- Febrile Neutropenia — 1 report (9.09%)
- Fungal Infection — 1 report (9.09%)
- Generalised Tonic-Clonic Seizure — 1 report (9.09%)
Other Oncology approved in United States
Frequently asked questions
Is Intrathecal Methotrexate approved in United States?
Intrathecal Methotrexate does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Intrathecal Methotrexate in United States?
Sun Yat-sen University is the originator. The local marketing authorisation holder may differ — check the official source linked above.